Recurrent GBM

​Trials listed below that do not have a blue link are not currently open to accrual


Protocol #

​Sponsor

​Title

​RTOG 0929 RTOG ​A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma.

 

​RTOG 1205 ​RTOG ​Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
​OSU 11122 ​Tocagen ​A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended-Release 5-FC

 

​OSU 12105 ​Tocagen ​A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

 

OSU 10151 ​OSU ​Intracerebral convection enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas

 

​OSU 13072 ​BTTC ​Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma

 

​OSU 13032 ​Tocagen ​A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent High Grade Glioma

 

​OSU 13096 ​Tracon ​A Phase 2 Evaluation of TRC105 in Combination with Bevacizumab for the Treatment of Recurrent or Progressive Glioblastoma that has Progressed on Bevacizumab

 

 

For more information:  

Jill Brown
Jill.Brown@osumc.edu
614-293-5554

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu